Back
Full-text
Journal article

Evidence for a role of sterol 27-hydroxylase in glucocorticoid metabolism in vivo.

  • Vögeli I Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital Berne, CH-3010 Berne, Switzerland Department of Neurology, University Hospital Zurich, Zurich, Switzerland Department of Medicine, University of California, San Francisco, California, USA Department of Internal Medicine, Emmental Hospital, Burgdorf, Switzerland Prince Henry's Institute, Clayton 3168, Victoria, Australia.
  • Jung HH
  • Dick B
  • Erickson SK
  • Escher R
  • Funder JW
  • Frey FJ
  • Escher G
Show more…
  • 2013-10-08
Published in:
  • The Journal of endocrinology. - 2013
(tetrahydrocorticosterone+5α-tetrahydrocorticosterone)/11-dehydrocorticosterone ratio
11β-hydroxysteroid dehydrogenase 1
27-hydroxycholesterol
Cyp27a1 KO mice
cerebrotendinous xanthomatosis
11-beta-Hydroxysteroid Dehydrogenase Type 1
Animals
Cholestanetriol 26-Monooxygenase
Disease Models, Animal
Female
Glucocorticoids
Homeostasis
Humans
In Vitro Techniques
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Mutation
Xanthomatosis, Cerebrotendinous
English The intracellular availability of glucocorticoids is regulated by the enzymes 11β-hydroxysteroid dehydrogenase 1 (HSD11B1) and 11β-hydroxysteroid dehydrogenase 2 (HSD11B2). The activity of HSD11B1 is measured in the urine based on the (tetrahydrocortisol+5α-tetrahydrocortisol)/tetrahydrocortisone ((THF+5α-THF)/THE) ratio in humans and the (tetrahydrocorticosterone+5α-tetrahydrocorticosterone)/tetrahydrodehydrocorticosterone ((THB+5α-THB)/THA) ratio in mice. The cortisol/cortisone (F/E) ratio in humans and the corticosterone/11-dehydrocorticosterone (B/A) ratio in mice are markers of the activity of HSD11B2. In vitro agonist treatment of liver X receptor (LXR) down-regulates the activity of HSD11B1. Sterol 27-hydroxylase (CYP27A1) catalyses the first step in the alternative pathway of bile acid synthesis by hydroxylating cholesterol to 27-hydroxycholesterol (27-OHC). Since 27-OHC is a natural ligand for LXR, we hypothesised that CYP27A1 deficiency may up-regulate the activity of HSD11B1. In a patient with cerebrotendinous xanthomatosis carrying a loss-of-function mutation in CYP27A1, the plasma concentrations of 27-OHC were dramatically reduced (3.8 vs 90-140 ng/ml in healthy controls) and the urinary ratios of (THF+5α-THF)/THE and F/E were increased, demonstrating enhanced HSD11B1 and diminished HSD11B2 activities. Similarly, in Cyp27a1 knockout (KO) mice, the plasma concentrations of 27-OHC were undetectable (<1 vs 25-120 ng/ml in Cyp27a1 WT mice). The urinary ratio of (THB+5α-THB)/THA was fourfold and that of B/A was twofold higher in KO mice than in their WT littermates. The (THB+5α-THB)/THA ratio was also significantly increased in the plasma, liver and kidney of KO mice. In the liver of these mice, the increase in the concentrations of active glucocorticoids was due to increased liver weight as a consequence of Cyp27a1 deficiency. In vitro, 27-OHC acts as an inhibitor of the activity of HSD11B1. Our studies suggest that the expression of CYP27A1 modulates the concentrations of active glucocorticoids in both humans and mice and in vitro.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/286301
Statistics
Document views: 37 File downloads:
  • Full-text: 0